newsfilter
← Latest News
GlobeNewswire·

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

GRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech company developing RNA interference (RNAi) therapies for